Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Author(s) -
Шломо Мелмед,
Vera Popović,
Martin Bidlingmaier,
Moisés Mercado,
Aart Jan van der Lely,
Nienke R. Biermasz,
Marek Bolanowski,
Mihail Coculescu,
Jochen Schopohl,
Kàroly Rácz,
Benjamin Gläser,
Miklós Góth,
Yona Greenman,
Peter Trainer,
Emese Mezősi,
Ilan Shimon,
Andrea Giustina,
Márta Korbonits,
Marcello D. Bronstein,
David L. Kleinberg,
Sam L. Teichman,
Irit GlikoKabir,
Roni Mamluk,
Asi Haviv,
Christian J. Strasburger
Publication year - 2015
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2014-4113
Subject(s) - acromegaly , medicine , octreotide , clinical endpoint , adverse effect , somatostatin , phases of clinical research , gastroenterology , multicenter study , clinical trial , randomized controlled trial , growth hormone , hormone
A novel oral octreotide formulation was tested for efficacy and safety in a phase III, multicenter, open-label, dose-titration, baseline-controlled study in patients with acromegaly.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom